| Code | Description | Claims | Beneficiaries | Total Paid |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
18,331 |
16,135 |
$2.16M |
| 93458 |
|
929 |
927 |
$1.55M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
5,425 |
5,341 |
$968K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,539 |
5,225 |
$915K |
| G0378 |
Hospital observation service, per hour |
2,703 |
2,619 |
$713K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,399 |
2,150 |
$535K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,820 |
2,704 |
$489K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
1,597 |
1,589 |
$437K |
| 78431 |
|
531 |
513 |
$407K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,928 |
1,864 |
$375K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,355 |
1,887 |
$371K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
3,985 |
3,930 |
$360K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,274 |
3,141 |
$232K |
| 93017 |
|
4,542 |
4,376 |
$216K |
| 80053 |
Comprehensive metabolic panel |
12,662 |
10,881 |
$214K |
| 70450 |
Computed tomography, head or brain; without contrast material |
895 |
884 |
$212K |
| 75574 |
|
833 |
831 |
$202K |
| 93226 |
|
1,222 |
1,219 |
$201K |
| 93225 |
|
1,285 |
1,281 |
$185K |
| J2785 |
Injection, regadenoson, 0.1 mg |
1,441 |
1,383 |
$176K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
802 |
766 |
$166K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
600 |
592 |
$159K |
| 83880 |
|
4,588 |
4,385 |
$125K |
| 93880 |
|
762 |
758 |
$122K |
| 86850 |
|
5,460 |
4,372 |
$119K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
2,450 |
2,378 |
$107K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
1,415 |
1,405 |
$104K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
359 |
357 |
$97K |
| 36415 |
Collection of venous blood by venipuncture |
16,249 |
11,781 |
$94K |
| 86901 |
|
5,461 |
4,374 |
$90K |
| 86900 |
|
5,491 |
4,395 |
$89K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
513 |
413 |
$85K |
| C9600 |
Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch |
41 |
38 |
$75K |
| 96367 |
|
753 |
565 |
$74K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
3,179 |
3,053 |
$64K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
204 |
201 |
$61K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
325 |
292 |
$55K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
287 |
284 |
$41K |
| 80061 |
Lipid panel |
4,364 |
4,208 |
$39K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
1,470 |
1,431 |
$38K |
| J3490 |
Unclassified drugs |
2,045 |
1,587 |
$38K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
18,111 |
17,259 |
$37K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
535 |
521 |
$35K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
255 |
114 |
$33K |
| 93307 |
|
180 |
178 |
$32K |
| J0248 |
Injection, remdesivir, 1 mg |
68 |
26 |
$31K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,272 |
1,084 |
$30K |
| 85610 |
|
8,558 |
7,886 |
$29K |
| A9555 |
Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries |
527 |
469 |
$29K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
106 |
94 |
$29K |
| Q0247 |
Injection, sotrovimab, 500 mg |
30 |
29 |
$28K |
| C1760 |
Closure device, vascular (implantable/insertable) |
584 |
569 |
$27K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
978 |
792 |
$26K |
| 93299 |
|
836 |
818 |
$22K |
| 93970 |
|
40 |
39 |
$19K |
| 85730 |
|
7,046 |
6,664 |
$17K |
| C1874 |
Stent, coated/covered, with delivery system |
25 |
25 |
$16K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,889 |
8,766 |
$14K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,244 |
2,230 |
$13K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
95 |
78 |
$13K |
| C1769 |
Guide wire |
1,060 |
1,039 |
$12K |
| 78434 |
|
120 |
105 |
$12K |
| 93296 |
|
128 |
128 |
$12K |
| 71046 |
Radiologic examination, chest; 2 views |
895 |
889 |
$12K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,156 |
2,059 |
$12K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,447 |
3,114 |
$12K |
| 92978 |
|
38 |
38 |
$10K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,617 |
2,151 |
$10K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
31 |
29 |
$10K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
49 |
45 |
$9K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
166 |
162 |
$8K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
37 |
37 |
$7K |
| 84702 |
|
2,625 |
2,477 |
$7K |
| 93298 |
|
560 |
558 |
$7K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
42 |
38 |
$7K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
24 |
19 |
$6K |
| 87631 |
|
118 |
117 |
$6K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
891 |
867 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
470 |
361 |
$5K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
180 |
175 |
$5K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
322 |
306 |
$4K |
| 75561 |
|
13 |
13 |
$3K |
| M0239 |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
16 |
15 |
$3K |
| 70496 |
|
13 |
13 |
$3K |
| 80050 |
General health panel |
132 |
128 |
$3K |
| 85027 |
|
1,611 |
1,368 |
$3K |
| 71045 |
Radiologic examination, chest; single view |
3,364 |
3,185 |
$3K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
37 |
37 |
$3K |
| 82947 |
|
2,639 |
1,838 |
$3K |
| 81025 |
|
805 |
799 |
$3K |
| 87581 |
|
179 |
174 |
$2K |
| 87486 |
|
179 |
174 |
$2K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,963 |
1,872 |
$2K |
| J1756 |
Injection, iron sucrose, 1 mg |
50 |
24 |
$2K |
| 81003 |
|
2,652 |
2,572 |
$2K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,435 |
1,305 |
$2K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
26 |
26 |
$2K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
170 |
163 |
$2K |
| 76641 |
|
59 |
56 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
595 |
588 |
$2K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
39 |
28 |
$1K |
| 83735 |
|
2,212 |
1,869 |
$1K |
| 83615 |
|
710 |
429 |
$1K |
| 84484 |
|
5,085 |
3,317 |
$930.45 |
| 87088 |
|
741 |
725 |
$910.38 |
| 96376 |
|
228 |
188 |
$824.78 |
| 88342 |
|
13 |
13 |
$750.37 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
157 |
153 |
$714.16 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
37 |
37 |
$592.35 |
| 93320 |
|
12 |
12 |
$584.93 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,363 |
2,071 |
$475.05 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
71 |
61 |
$423.15 |
| 75565 |
|
12 |
12 |
$420.35 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
12 |
12 |
$394.47 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
1,544 |
1,187 |
$378.26 |
| 78492 |
|
105 |
73 |
$337.76 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,624 |
1,297 |
$328.65 |
| S0028 |
Injection, famotidine, 20 mg |
756 |
604 |
$313.52 |
| J7050 |
Infusion, normal saline solution, 250 cc |
2,517 |
1,588 |
$309.75 |
| 83605 |
|
1,598 |
1,441 |
$255.73 |
| 82977 |
|
113 |
96 |
$247.72 |
| 85379 |
|
1,165 |
1,138 |
$247.65 |
| 0482T |
|
72 |
46 |
$229.86 |
| J2704 |
Injection, propofol, 10 mg |
1,858 |
1,406 |
$227.93 |
| C1889 |
Implantable/insertable device, not otherwise classified |
31 |
31 |
$195.19 |
| Q0239 |
Injection, bamlanivimab-xxxx, 700 mg |
15 |
14 |
$194.79 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,051 |
1,694 |
$185.64 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
549 |
417 |
$181.20 |
| 93325 |
|
25 |
25 |
$162.84 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
19 |
17 |
$161.97 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
85 |
85 |
$156.58 |
| 83690 |
|
1,126 |
1,070 |
$127.04 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
561 |
513 |
$70.92 |
| 82550 |
|
37 |
37 |
$62.94 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,830 |
1,773 |
$50.85 |
| 84145 |
|
201 |
197 |
$47.26 |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,217 |
1,053 |
$40.00 |
| 87040 |
|
159 |
81 |
$34.30 |
| 86141 |
|
39 |
37 |
$20.60 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,360 |
1,053 |
$20.58 |
| 85651 |
|
45 |
42 |
$7.94 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
243 |
209 |
$7.20 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
75 |
65 |
$6.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
13 |
12 |
$5.73 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
91 |
68 |
$5.63 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
168 |
163 |
$1.10 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
24 |
16 |
$0.90 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
13 |
13 |
$0.50 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
16 |
13 |
$0.00 |
| C1753 |
Catheter, intravascular ultrasound |
12 |
12 |
$0.00 |
| 78499 |
|
36 |
27 |
$0.00 |
| 87428 |
|
13 |
12 |
$0.00 |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
289 |
255 |
$0.00 |
| 99080 |
|
267 |
61 |
$0.00 |